Research Article: When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
Introduction:
Severe asthma features a chronic airway inflammation mediated by many interleukins [1, 2]. The advent of biologics directed toward T2 cytokines has changed the course of the disease and the quality of life of many severe asthmatics qualified as being T2 high patients. There are currently five classes of biologics approved for treating severe asthma, including anti-immunoglobulin E (anti-IgE) (omalizumab), anti-interleukin (IL)-5 (mepolizumab, reslizumab), anti-IL5R (benralizumab), anti-IL4/IL13R (dupilumab), and…
Read more